Journal of Thoracic Oncology最新文献

{"title":"38P: Two years of follow-up data of a phase II clinical trial of atezolizumab with bevacizumab for patients with PD-L1 high expression non-squamous non-small cell lung cancer (WJOG10718L/@ Be Study)","authors":"T. Seto , M. Shimokawa , R. Toyozawa , S. Sugawara , H. Hayashi , H. Murakami , T. Kato , S. Niho , M. Oki , H. Yoshioka , H. Daga , K. Azuma , S. Miura , K. Nishino , M. Satouchi , I. Okamoto , N. Yamamoto","doi":"10.1016/S1556-0864(25)00233-3","DOIUrl":"10.1016/S1556-0864(25)00233-3","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Pages S34-S35"},"PeriodicalIF":21.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"45P: Extended follow-up confirmed real-world efficacy and safety of cemiplimab monotherapy in advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression","authors":"S. Masini , R. Alvarez Cabellos , I. De Elejoste Echebarria , M. Martinez Kareaga , M. Antonanzas Basa , M.C. Escoin Perez , F. Navarro , C. Traseira Puchol , L. Cabezon Gutierrez , S. Falagán Martínez , C. Garcia Benito , L. Masfarre Pinto , C. Avila Andrade , S. Sequero , J. Mosquera Martinez , E. Garcia Lorenzo , A. Azkárate Martínez , L. Paz-Ares , J. Zugazagoitia , J. Baena Espinar","doi":"10.1016/S1556-0864(25)00240-0","DOIUrl":"10.1016/S1556-0864(25)00240-0","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Pages S39-S40"},"PeriodicalIF":21.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143726154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"46P: Comparison of camrelizumab, pembrolizumab, tislelizumab, and sintilimab as first-line treatment in patients with non-small cell lung cancer: A retrospective study","authors":"S. Yu, Y. Xiaoqi","doi":"10.1016/S1556-0864(25)00241-2","DOIUrl":"10.1016/S1556-0864(25)00241-2","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Page S40"},"PeriodicalIF":21.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143726155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"62P: Firmonertinib (formerly furmonertinib) combined with anlotinib in patients with treatment-naive EGFR-mutant non-small cell lung cancer: Updated results from FOCUS-A study","authors":"B. Han , T. Chu , G. Yu , Z. Yu , X. Wang , J. Qian","doi":"10.1016/S1556-0864(25)00257-6","DOIUrl":"10.1016/S1556-0864(25)00257-6","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Page S49"},"PeriodicalIF":21.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143726244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"1O: Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD","authors":"X. Le , L. Hendriks , A. Morabito , L. Bonanno , I. Okamoto , J.W. Goldman , H.A. Yu , O.T. Brustugun , T.O. Halvorsen , Y.J. Kim , K. Marrone , B.C. Cho , J.W. Riess , A.J. De Langen , Z. Piotrowska , H. Ambrose , P. Smith , J.M. Lehman , P.G. Fraenkel , S.B. Goldberg","doi":"10.1016/S1556-0864(25)00196-0","DOIUrl":"10.1016/S1556-0864(25)00196-0","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Pages S2-S4"},"PeriodicalIF":21.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929","authors":"Nagla Abdel Karim MD, PhD ,&nbsp;Jieling Miao MS ,&nbsp;Karen L. Reckamp MD ,&nbsp;Carl M. Gay MD, PhD ,&nbsp;Lauren A. Byers MD, MS ,&nbsp;Ying-Qi Zhao PhD ,&nbsp;Mary W. Redman PhD ,&nbsp;Daniel R. Carrizosa MD, MS ,&nbsp;Wei-Lien Wang MD ,&nbsp;William J. Petty MD ,&nbsp;Kathan Mehta MD, MPH ,&nbsp;Bryan A. Faller MD ,&nbsp;Edem S. Agamah MD ,&nbsp;Samer S. Kasbari MD, MS ,&nbsp;Rajini K. Malisetti MD ,&nbsp;Atul Kumar MD, PhD ,&nbsp;John Schallenkamp MD, MBA ,&nbsp;Krishna C. Alluri MD ,&nbsp;Jhanelle E. Gray MD ,&nbsp;Karen Kelly MD","doi":"10.1016/j.jtho.2024.10.021","DOIUrl":"10.1016/j.jtho.2024.10.021","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate whether the addition of a poly (adenosine diphosphate–ribose) polymerase inhibitor talazoparib to maintenance immune checkpoint inhibitor atezolizumab after frontline chemoimmunotherapy improved outcomes in patients with Schlafen 11 (SLFN11)-positive extensive-stage SCLC (ES-SCLC).</div></div><div><h3>Methods</h3><div>Patients with newly diagnosed SLFN11 expressing (H-score ≥ 1, evaluated centrally) ES-SCLC were randomized to maintenance atezolizumab (A) versus atezolizumab plus talazoparib (AT) after frontline chemotherapy plus atezolizumab. The primary objective was to compare progression-free survival (PFS) using a one-sided 10% level stratified log-rank test. Secondary endpoints included objective response rate, overall survival, and toxicity. The target sample size was 84 eligible patients.</div></div><div><h3>Results</h3><div>From June 15, 2020, to December 15, 2022, 106 eligible patients were randomized (54 to AT and 52 to A). Progression-free survival was improved with AT versus A (hazard ratio = 0.66, 80% confidence interval: 0.50–0.86, one-sided <em>p</em> = 0.019) with a median PFS of 2.9 and 2.4 months; overall survival was not different between groups (hazard ratio = 0.98, 80% confidence interval: 0.71–1.36, one-sided <em>p</em> = 0.47). Grade 3 and higher non-hematologic treatment-related adverse events occurred in 17% of patients with AT and 14% of patients with A. Grade 3 and higher hematological treatment-related adverse events were more common in AT (50%) than in A (4%) (<em>p</em> &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>Maintenance AT improved PFS in patients with SLFN11-positive ES-SCLC that did not progress after initial chemo-immunotherapy. Hematologic toxicity, primarily grade 3 anemia, was increased with AT, as expected. Prospective biomarker selection was demonstrated, paving the way for future evaluation of novel therapies in molecularly defined SCLC populations.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Pages 383-394"},"PeriodicalIF":21.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study","authors":"Shun Lu MD, PhD ,&nbsp;Lin Wu MD, PhD ,&nbsp;Qiming Wang MD ,&nbsp;Ziping Wang MD ,&nbsp;Dongqing Lv MD ,&nbsp;Rui Ma MD ,&nbsp;Bo Zhu MD, PhD ,&nbsp;Ngoc van Tran MD, PhD ,&nbsp;Liyan Jiang MD, PhD ,&nbsp;Kejun Nan PhD ,&nbsp;Konstantin Laktionov MD ,&nbsp;Stephen Clarke MD, PhD ,&nbsp;Minghao Song MD ,&nbsp;Helen Mann MSc ,&nbsp;Yinglei Liu MD ,&nbsp;Xiaojin Shi MD ,&nbsp;Yi-Long Wu MD","doi":"10.1016/j.jtho.2024.10.024","DOIUrl":"10.1016/j.jtho.2024.10.024","url":null,"abstract":"<div><h3>Introduction</h3><div>PEARL (NCT03003962) is an open-label, phase 3 study comparing first-line durvalumab monotherapy with chemotherapy in patients with metastatic NSCLC (mNSCLC [<em>EGFR/ALK</em> wild type]) with programmed cell death ligand 1 (PD-L1) tumor cell (TC) membrane expression status of 25% or higher. We report the final analysis of PEARL.</div></div><div><h3>Methods</h3><div>Adults (N = 669) with previously untreated stage IV mNSCLC were randomized (1:1) to durvalumab 20 mg/kg every four weeks or chemotherapy every three weeks for four to six cycles. The dual primary endpoints were overall survival (OS) in the population with PD-L1 TC of 25% or higher and OS in the population at low risk of early mortality (LREM) with PD-L1 TC of 25% or higher.</div></div><div><h3>Results</h3><div>Durvalumab was associated with a numerical reduction in the risk of death versus chemotherapy in the 25% and higher PD-L1 TC population (OS hazard ratio [HR] = 0.84, 95% confidence interval [CI]: 0.71–0.99, <em>p</em> = 0.037; median OS 14.6 months, 95% CI: 12.2–16.9 versus 12.8 months, 95% CI: 10.1–14.7, respectively). In the 25% and higher PD-L1 TC low risk of early mortality population the OS hazard ratio for durvalumab versus chemotherapy was 0.96 (95% CI: 0.79–1.15, <em>p</em> = 0.628); median OS 14.6 months (95% CI: 12.6–17.2) versus 15.0 months (95% CI: 13.1–16.8), respectively. In the safety population, the incidence of grade 3 or 4 treatment-related adverse events was 15.5% (durvalumab) and 45.9% (chemotherapy).</div></div><div><h3>Conclusions</h3><div>Durvalumab did not statistically significantly improve OS versus chemotherapy as first-line treatment in patients with mNSCLC and 25% and higher PD-L1 TC. The numerical improvement in OS was consistent with previous studies of first-line immune checkpoint inhibitor monotherapy in patients with mNSCLC.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Pages 366-382"},"PeriodicalIF":21.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FGTI-2734 Inhibits ERK Reactivation to Overcome Sotorasib Resistance in KRAS G12C Lung Cancer","authors":"Aslamuzzaman Kazi PhD ,&nbsp;Hitesh Vasiyani PhD ,&nbsp;Deblina Ghosh PhD ,&nbsp;Dipankar Bandyopadhyay PhD ,&nbsp;Rachit D. Shah MD ,&nbsp;Vignesh Vudatha MD ,&nbsp;Jose Trevino MD ,&nbsp;Said M. Sebti PhD","doi":"10.1016/j.jtho.2024.11.022","DOIUrl":"10.1016/j.jtho.2024.11.022","url":null,"abstract":"<div><h3>Introduction</h3><div>KRAS G12C targeted therapies, such as sotorasib, represent a major breakthrough, but overall response rates and progression-free survival for patients with KRAS G12C lung cancer are modest due to the emergence of resistance mechanisms involving adaptive reactivation of ERK, which requires wild-type HRAS and NRAS membrane localization.</div></div><div><h3>Methods and Results</h3><div>Here, we demonstrate that the dual farnesyltransferase and geranylgeranyltransferase-1 inhibitor FGTI-2734 inhibits wild-type RAS membrane localization and sotorasib-induced ERK feedback reactivation, and overcomes sotorasib adaptive resistance. The combination of FGTI-2734 and sotorasib is synergistic at inhibiting the viability and inducing apoptosis of KRAS G12C lung cancer cells, including those highly resistant to sotorasib. FGTI-2734 enhances sotorasib’s anti-tumor activity <em>in vivo</em> leading to significant tumor regression of a patient-derived xenograft (PDX) from a patient with KRAS G12C lung cancer and several xenografts from highly sotorasib-resistant KRAS G12C human lung cancer cells. Importantly, treatment of mice with FGTI-2734 inhibited sotorasib-induced ERK reactivation in KRAS G12C PDX, and treatment of mice with the combination of FGTI-2734 and sotorasib was also significantly more effective at suppressing <em>in vivo</em> the levels of P-ERK in sotorasib-resistant human KRAS G12C lung cancer xenografts and the NSCLC PDX.</div></div><div><h3>Conclusion</h3><div>Our findings provide a foundation for overcoming sotorasib resistance and potentially improving the treatment outcomes of KRAS G12C lung cancer.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Pages 331-344"},"PeriodicalIF":21.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142739924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reducing pERKs to Break “RAS”istance to Sotorasib","authors":"Steven G. Gray PhD ,&nbsp;Diarmuid O’Connor MB BCH BAO ,&nbsp;Luciano Mutti MD, PhD ,&nbsp;Tomer Meirson MD, PhD","doi":"10.1016/j.jtho.2025.01.002","DOIUrl":"10.1016/j.jtho.2025.01.002","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Pages 259-261"},"PeriodicalIF":21.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143535272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4O: Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study","authors":"J.C-H. Yang ,&nbsp;Y.J. Kim ,&nbsp;S-H. Lee ,&nbsp;B. Liu ,&nbsp;Y.V. Ostapenko ,&nbsp;S. Lu ,&nbsp;A. Alip ,&nbsp;E.P. Korbenfeld ,&nbsp;J. Dias ,&nbsp;P. Danchaivijitr ,&nbsp;N. Girard ,&nbsp;E. Felip ,&nbsp;H. Hayashi ,&nbsp;A. Spira ,&nbsp;B. Besse ,&nbsp;T. Sun ,&nbsp;M. Ennis ,&nbsp;S. Sethi ,&nbsp;J.M. Bauml ,&nbsp;B.C. Cho","doi":"10.1016/S1556-0864(25)00199-6","DOIUrl":"10.1016/S1556-0864(25)00199-6","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Pages S6-S8"},"PeriodicalIF":21.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}